RxDoctor Payments DataLook up a doctor →

Michael Chen, MD

Internal Medicine · Stayton, ORNPI 1619926011

Payments from drug & device makers

$1,235,298in general payments, 2019–2025

Across 187 payments — averaging $6605.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$589K
  • Eli Lilly$552K
  • Novo Nordisk AS$83K
  • Sanofi US Services Inc.$11K
  • Amgen$146
  • Pfizer$64
  • plus $328 from 12 others
$14,592in research payments, 2019–2025

Across 6 payments — averaging $2432.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$15K

What the payments were for

  • Speaking & faculty fees$8015%
  • Food & beverage$44282%
  • Education$163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,235,298 in reported general payments places this provider in the 95th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$3,024
Medicare patients
24
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide172$238,777
JardianceEmpagliflozin157$206,456
EliquisApixaban124$148,010
TrulicityDulaglutide78$113,510
MounjaroTirzepatide68$99,493
FarxigaDapagliflozin Propanediol37$44,477
Bydureon BciseExenatide Microspheres31$30,065
EntrestoSacubitril/Valsartan14$25,887
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$20,014
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$17,006
Arnuity ElliptaFluticasone Furoate31$9,116
Incruse ElliptaUmeclidinium Bromide23$7,920
Rosuvastatin Calcium505$7,658
Breo ElliptaFluticasone/Vilanterol17$6,444
SynthroidLevothyroxine Sodium65$6,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$148,010124 claims
AstraZenecaFarxiga$16$44,47737 claims
GSKTrelegy Ellipta, Arnuity Ellipta, Incruse Ellipta, Breo Ellipta$39$43,49397 claims
NovartisEntresto$39$25,88714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Stayton

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →